Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report)’s share price was down 4.4% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $12.10 and last traded at $12.10. Approximately 38,531 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 75,509 shares. The stock had previously closed at $12.66.
Specifically, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the sale, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Gyre Therapeutics Stock Down 4.4 %
The company’s fifty day moving average is $12.64 and its two-hundred day moving average is $12.67.
Hedge Funds Weigh In On Gyre Therapeutics
About Gyre Therapeutics
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
- Five stocks we like better than Gyre Therapeutics
- Where to Find Earnings Call Transcripts
- 3 Stocks Helping to Bring AI to Healthcare
- Business Services Stocks Investing
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- 3 Monster Growth Stocks to Buy Now
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.